GlassScriptPhysician profile
Juan D Diaz
NPI 1831272061
$979,913.03
in general payments reported to CMS, 2019-2025
25 companies · $148K in 2025
The $148K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218K · 2020: $54K · 2021: $93K · 2022: $91K · 2023: $204K · 2024: $173K · 2025: $148K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $277K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $124K · Travel and Lodging: $57K · Honoraria: $37K · Food and Beverage: $16K · Consulting Fee: $13K · Education: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $276,977.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $124,230.00 |
| Travel and Lodging | $56,659.36 |
| Honoraria | $37,155.00 |
| Food and Beverage | $15,869.30 |
| Consulting Fee | $13,460.00 |
| Education | $339.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187,287.18 | 2021-2025 | Dalvance, Teflaro, Avycaz |
| Shionogi INC | $170,285.11 | 2021-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $146,733.25 | 2019-2025 | Prevymis, Zerbaxa, Dificid |
| Melinta Therapeutics, LLC | $121,411.13 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Takeda Pharmaceuticals U.S.A., INC. | $116,781.88 | 2022-2025 | Livtencity |
| Allergan, INC. | $95,742.94 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $80,826.59 | 2021-2025 | Xerava, Xacduro, Zevtera |
| Insmed, INC. | $37,135.54 | 2019-2025 | Arikayce, Brinsupri |
| Tetraphase Pharmaceuticals, INC. | $17,908.47 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $2,004.17 | 2022-2023 | Rebyota |
| Cipla USA INC. | $1,624.44 | 2019-2021 | |
| Astellas Pharma US INC | $908.11 | 2019-2025 | Cresemba |
| Paratek Pharmaceuticals, INC. | $464.08 | 2021-2025 | Nuzyra |
| Gilead Sciences, INC. | $245.45 | 2019-2023 | |
| Janssen Biotech, INC. | $172.27 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $88.62 | 2025 | Vowst |
| Kerecis Limited | $85.69 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Janssen Products, LP | $49.95 | 2021 | |
| Mayne Pharma Commercial LLC | $42.09 | 2020 | |
| Shire North American Group INC | $27.11 | 2019 | |
| Accelerate Diagnostics INC. | $26.00 | 2019 | |
| Smith+Nephew, INC. | $24.18 | 2024 | Collagenase Santyl |
| Glaxosmithkline, LLC. | $13.96 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.13 | 2023 | Vibativ |
| Dynavax Technologies Corporation | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.